Lila Bio logo

Lila Bio

lila.bio

Lila Bio develops therapeutic proteins using AI-powered protein design and experimental discovery platforms. Its targeted radiotherapy platform focuses on solid tumors, while its long-acting injectable platform targets non-oncology diseases; the company aims to develop medicines that improve care for people with cancer and other debilitating diseases.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2023
Employees
10
Members see funding amounts.
.
Founders
Jake Kraft, PhD, Anindya Roy, PhD, Hua Bai, PhD, Sheila Gujrathi, MD

Is this your organization? Claim it

Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed long‑acting injectable for pulmonary hypertension

Lila Bio, spun out of David Baker’s UW lab, won a $3.65 million NIH SBIR grant to develop an AI-designed, long-acting injectable protein therapy aimed at modifying disease in pulmonary hypertension. The funding covers two phases—$605,981 for initial animal studies and $3,049,462 for further animal work and patient lung-tissue studies—and builds on Lila’s 2023 $10M seed raise and prior collaboration with Eli Lilly.

Lila Bio wins $3.65M NIH SBIR grant to build AI-designed proteins for pulmonary hypertension

Lila Bio won a $3.65 million NIH SBIR fast-track grant to develop AI-designed therapeutic proteins for pulmonary hypertension, receiving an initial $605,981 phase followed by $3,049,462 in a second phase. The Seattle startup, founded in 2023 by Jake Kraft and Anindya Roy, previously raised a $10 million seed round and will use the non-dilutive funding to advance candidates toward clinical utility.

See all 11 stories, episodes and videos about Lila Bio.

People

See all 4
  • Anindya Roy
    Anindya Roy Executive Officer, Director, CSO & Co-Founder
  • Jake Kraft
    Jake Kraft CEO & Co-Founder
  • Hua Bai Director of Protein Design & Co-Founder

Online